Genelux Corporation (GNLX)
(Delayed Data from NSDQ)
$2.54 USD
0.00 (0.00%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Genelux Corporation (GNLX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$19.20 | $32.00 | $10.00 | 655.91% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Genelux Corporation comes to $19.20. The forecasts range from a low of $10.00 to a high of $32.00. The average price target represents an increase of 655.91% from the last closing price of $2.54.
Analyst Price Targets (5 )
Broker Rating
Genelux Corporation currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/27/2024 | Roth Capital Partners | Benjamin E Paluch | Not Available | Strong Buy |
8/16/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
8/15/2024 | H.C. Wainwright & Co. | Emily Bodnar | Strong Buy | Strong Buy |
5/31/2024 | Brookline Capital Markets | Kemp Dolliver | Strong Buy | Strong Buy |
4/3/2024 | The Benchmark Company | Bruce D Jackson | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $19.20 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.19 |
GNLX FAQs
Genelux Corporation (GNLX) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 5 brokerage firms.
The average price target for Genelux Corporation (GNLX) is $19.20. The current on short-term price targets is based on 3 reports.
The forecasts for Genelux Corporation (GNLX) range from a low of $10 to a high of $32. The average price target represents a increase of $655.91 from the last closing price of $2.54.
The current UPSIDE for Genelux Corporation (GNLX) is 655.91%
Based on short-term price targets offered by five analysts, the average price target for Genelux Corporation comes to $19.20. The forecasts range from a low of $10.00 to a high of $32.00. The average price target represents an increase of 655.91% from the last closing price of $2.54.